Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR 1,773.40
+3.50 (0.20%)
Nov 4, 2026, 3:29 PM IST
NSE:SUNPHARMA Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 4,254,981 | 4,216,111 | 4,162,126 | 3,888,242 | 2,358,729 | 2,194,737 | |
Market Cap Growth | 3.93% | 1.30% | 7.04% | 64.84% | 7.47% | 53.02% |
Enterprise Value | 3,954,531 | 3,992,527 | 3,989,271 | 3,792,904 | 2,296,495 | 2,136,376 |
Last Close Price | 1773.40 | 1752.61 | 1713.36 | 1586.00 | 953.31 | 877.54 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 38.80 | 36.73 | 38.08 | 40.60 | 27.84 | 67.06 |
Forward PE | 30.53 | 34.42 | 35.80 | 42.36 | 28.97 | 28.54 |
PS Ratio | 6.90 | 7.21 | 7.92 | 8.02 | 5.38 | 5.68 |
PB Ratio | 4.75 | 5.03 | 5.74 | 5.79 | 3.98 | 4.30 |
P/TBV Ratio | 6.51 | 7.01 | 7.67 | 8.39 | 6.16 | 6.23 |
P/FCF Ratio | 54.74 | 47.86 | 34.85 | 39.14 | 82.08 | 29.30 |
P/OCF Ratio | 39.47 | 33.95 | 29.58 | 32.04 | 47.56 | 24.43 |
PEG Ratio | 1.98 | 2.66 | 2.39 | 2.97 | 1.99 | 1.46 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 6.42 | 6.83 | 7.59 | 7.82 | 5.23 | 5.53 |
EV/EBITDA Ratio | 22.96 | 24.47 | 26.65 | 29.46 | 19.71 | 21.04 |
EV/EBIT Ratio | 27.68 | 29.33 | 31.65 | 36.05 | 24.68 | 26.19 |
EV/FCF Ratio | 50.87 | 45.32 | 33.40 | 38.18 | 79.91 | 28.53 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.04 | 0.06 | 0.03 | 0.05 | 0.12 | 0.03 |
Debt / EBITDA Ratio | 0.19 | 0.28 | 0.16 | 0.25 | 0.58 | 0.13 |
Debt / FCF Ratio | 0.42 | 0.53 | 0.20 | 0.33 | 2.40 | 0.17 |
Net Debt / Equity Ratio | -0.34 | -0.34 | -0.33 | -0.24 | -0.14 | -0.22 |
Net Debt / EBITDA Ratio | -1.77 | -1.77 | -1.59 | -1.23 | -0.71 | -1.12 |
Net Debt / FCF Ratio | -3.90 | -3.28 | -1.99 | -1.59 | -2.87 | -1.52 |
Asset Turnover | 0.56 | 0.58 | 0.59 | 0.58 | 0.58 | 0.56 |
Inventory Turnover | 1.11 | 1.09 | 1.10 | 1.08 | 1.12 | 1.17 |
Quick Ratio | 2.18 | 2.18 | 2.18 | 1.82 | 1.36 | 1.37 |
Current Ratio | 2.94 | 2.82 | 2.89 | 2.56 | 2.00 | 2.03 |
Return on Equity (ROE) | 13.10% | 14.72% | 15.71% | 15.20% | 15.43% | 6.74% |
Return on Assets (ROA) | 8.20% | 8.47% | 8.87% | 7.91% | 7.73% | 7.42% |
Return on Invested Capital (ROIC) | 18.40% | 20.05% | 20.12% | 17.87% | 18.65% | 14.83% |
Return on Capital Employed (ROCE) | 15.70% | 15.80% | 17.10% | 15.40% | 15.30% | 15.50% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.58% | 2.72% | 2.63% | 2.46% | 3.59% | 1.49% |
FCF Yield | 1.83% | 2.09% | 2.87% | 2.56% | 1.22% | 3.41% |
Dividend Yield | 0.90% | 0.91% | 0.92% | 0.83% | 1.17% | 1.09% |
Payout Ratio | 34.78% | 34.27% | 33.07% | 30.26% | 29.73% | 65.97% |
Total Shareholder Return | 1.00% | 0.91% | 0.92% | 0.83% | 1.17% | 1.09% |